Convergent Therapeutics is welcoming Andrew Davis as the company’s new Chief Business and Strategy Officer. Davis, who currently serves on the Vedanta Biosciences Board of Directors, was most recently Chief Business Officer at Dynavax Therapeutics. What Convergent Therapeutics Does Convergent is a clinical-stage biotechnology company that focuses on development of next-generation tumor-selective alpha radioantibodies for cancer treatment. The company’s work harnesses antibody selectivity a...